Absci (ABSI) vs OneMedNet (ONMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed OneMedNet (ONMD) over the past year, gaining 146.5% versus a loss of 81.1%. Over five years, ABSI leads with a -13.3% price change compared with -95.1% for ONMD. Absci is the larger company by market cap ($1.53 billion vs $28.0 million), about 54.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | ONMD |
|---|---|---|
| Share price | $8.94 | $4.81 |
| Market cap | $1.53B | $27.99M |
| 1-day change | -3.09% | -2.13% |
| YTD return | +164.18% | -55.36% |
| 1-year return | +146.52% | -81.12% |
| 5-year return | -13.26% | -95.12% |
| EPS (TTM) | $-0.79 | $-1.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $42.20 |
| 52-week low | $2.24 | $4.73 |
| Distance from 52-week high | -25.88% | -88.61% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +61.16% | — |
| Average volume | 3.45M | 114.91K |
| Shares outstanding | 171.61M | 5.82M |
| Employees | 140 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Absci is about 54.8 times larger than OneMedNet by market value ($1.53B vs $27.99M).
- ABSI has outperformed ONMD by 227.6 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
ABSI vs ONMD FAQ
Which is bigger, Absci or OneMedNet?
Absci (ABSI) is larger, with a market capitalization of $1.53B compared with $27.99M for OneMedNet (ONMD).
Which stock has performed better over the past year, ABSI or ONMD?
ABSI returned +146.52% over the past 12 months, compared with -81.12% for ONMD (price return, excluding dividends). Past performance does not predict future results.
Are Absci and OneMedNet in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.